Kincell Bio announced the completion of a $22 million round, led by a new investor, NewSpring Capital, through its healthcare strategy, NewSpring Healthcare. Existing investor Kineticos Life Sciences also led the round.

Kincell Bio is a scientifically focused, cell therapy development and manufacturing company. This funding marks a significant milestone in Kincell Bio’s mission to transform the delivery of advanced cell therapies to patients worldwide. 

This new investment will accelerate Kincell Bio’s expansion of its cGMP capabilities, enhance its process development services, and support the development of innovative solutions tailored to emerging cell therapy companies. 

Kincell Bio’s platform offers clients a personalized, responsive, and expert-driven approach to process development and manufacturing from early clinical to pivotal supply and commercial launch, ensuring rapid timelines without compromising on quality.

The company also appointed Pete Buzy, former President and CEO of Catalent Cell & Gene Therapy, to its Board of Directors.

“We are excited to partner with the experienced team at NewSpring and to have them join our existing investors to support Kincell Bio, as we continue to scale our operations and deliver high-quality, flexible, and scalable solutions to our partners in the cell therapy space,” said Mark R. Bamforth, CEO of Kincell Bio. “Adding Pete Buzy to our board brings unparalleled insight into the complexities and opportunities within the advanced therapies sector and we are excited to partner with him and the NewSpring team.”